2-methyl-5-n-propyl-1,3,4-oxadiazole | 13148-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methyl-5-n-propyl-1,3,4-oxadiazole
• 英文别名: 2-Methyl-5-propyl-<1,3,4>oxadiazol；2-methyl-5-propyl-[1,3,4]oxadiazole；2-Methyl-5-propyl-1,3,4-oxadiazole
• CAS: 13148-67-9
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: IRBMIURUDWUKLU-UHFFFAOYSA-N

物化性质

• 沸点：
  87 °C(Press: 12 Torr)
• 密度：
  1.015±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-Acetyl-2-butyliden-hydrazin 在 sodium acetate 作用下， 以 甲醇 为溶剂， 以47%的产率得到2-methyl-5-n-propyl-1,3,4-oxadiazole
  参考文献：
  名称：

  Electrooxidative cyclization of N-acylhydrazones of aldehydes and ketones to .DELTA.3-1,3,4-oxadiazolines and 1,3,4-oxadiazoles

  摘要：

  The electrolytic oxidation of ketone N-acylhydrazones (1) in methanolic sodium acetate induced their intramolecular cyclization to the corresponding 2-methoxy-DELTA(3)-1,3,4-oxadiazolines 3. The thermal stability of a given oxadiazoline and what products were formed by its thermal decomposition was found to depend on the natures of the substituents at C-2. Thus, 2-methoxy-2-phenyloxadiazolines preferentially yielded oxiranes 5, whereas 2-alkyl-2-methoxyoxadiazolines preferentially gave enol ethers 6. 2,2-Dimethoxyoxadiazolines decomposed to the parent ketones and many unidentified products. The electrolytic oxidation of aldehyde N-acylhydrazones 2 gave 2,5-disubstituted 1,3,4-oxadiazoles 4. The oxidative cyclization of the N-benzoylhydrazones of aliphatic aldehydes gave especially high yields of the corresponding heterocycles.

  DOI：

  10.1021/jo00031a014

文献信息

• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057916A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及式1的取代4-吡啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• [EN] 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] ANALOGUES DE 2-AMINOARYL-5-ARYLOXAZOLE DESTINÉS AU TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：SOUTHERN RES INST

  公开号：WO2019164996A1

  公开（公告）日：2019-08-29

  The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-κΒ signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及能够激活NF-κΒ信号通路的2-氨基芳基-5-芳氧唑化合物。本公开还涉及使用这些化合物治疗神经系统疾病的方法，例如肌萎缩侧索硬化症（ALS）、阿尔茨海默病、帕金森病、脊髓性肌萎缩、创伤性脑损伤、血管性痴呆、亨廷顿病、智力障碍以及注意力缺陷和多动症（ADHD），以及神经肌肉疾病，例如杜兴氏肌营养不良（DMD）。本摘要旨在作为在特定领域中搜索的扫描工具，并不意味着对本发明的限制。
• [EN] METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：YUMANITY THERAPEUTICS INC

  公开号：WO2020150423A1

  公开（公告）日：2020-07-23

  The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本公开提供了在治疗神经系统疾病中有用的化合物和方法。本发明的化合物可以单独或与其他药用活性剂结合使用，用于治疗或预防神经系统疾病。
• [EN] PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE<br/>[FR] DÉRIVÉS DE PYRAZOLE QUI MODULENT LA STÉAROYL-COA DÉSATURASE
  申请人：NOVARTIS AG

  公开号：WO2011039358A1

  公开（公告）日：2011-04-07

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了能够调节硬脂酰辅酶A脱饱和酶活性的杂环衍生物。还涵盖了利用这些衍生物调节硬脂酰辅酶A脱饱和酶活性的方法以及包含这些衍生物的药物组合物。
• Cannabinoid receptor modulators
  申请人：Chackalamannil Samuel

  公开号：US20070197628A1

  公开（公告）日：2007-08-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

  具有通式（I）的一种化合物：或其药用盐、溶剂合物或酯，可用于治疗肥胖、代谢紊乱、成瘾、中枢神经系统疾病、心血管疾病、呼吸系统疾病和消化系统疾病等疾病、紊乱或症状。